Medical Marijuana, Inc. unworried of a Trump crackdown on CBD market

Medical Marijuana, Inc., the first publicly traded cannabis company in the United States, want to reassure people their operations in the federally legal hemp cannabidiol (CBD) market are unaffected by recent statements from Trump administration officials hinting at a crackdown on recreational cannabis.

“We would like to assure the public and shareholders alike of our continued compliance with all federal and state laws regarding medical cannabis and hemp CBD,” said CEO Stuart Titus. “The Trump administration’s recent comments on recreational marijuana have no bearing on our company, and no effect on our goals and vision for the future. Further, we believe the administration’s comments were quite favorable toward medical cannabis – and certainly our company believes in the therapeutic potential for all cannabinoids. As a society, we are happy to see the overall cannabis/cannabinoid dialogue moving forward, albeit at a snail’s pace here in the USA.”

Concerns have arisen after White House press secretary Sean Spicer’s comments regarding “greater enforcement” of federal cannabis laws by the Trump administration. However, he also affirmed President Trump’s consideration of the “pain and suffering that many people go through who are facing, especially terminal diseases, and the comfort … medical marijuana can bring to them.”

Medical Marijuana, Inc. is a diversified investment portfolio, with international drug import approvals in Mexico and Brazil. The company also has investments in pharmaceutical and biotech companies like AXIM Biotechnologies and Kannalife Sciences conducting clinical research for what will be FDA-approved medications.